Aduro Biotech Inc.

Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Providence Health & Services - Oregon

Portland State University

Providence Health & Services

Keith Sadoon Bahjat

Alan J Korman

Thomas W Dubensky, Jr

Dirk G Brockstedt

Paul O Sheppard

Arvind Rajpal

Ginger Chao Rakestraw

Andrew Rankin

Robert J Johnston

Lin Hui Su

Luis Borges

Guodong Chen

Richard Y Huang

Ekaterina G Deyanova

Peter M Lauer

Meredith Lai Ling Leong

Andy X Deng

Xiaodi Deng

Jason Robert Pinckney

David A Critton

Meredith Leong

Yoshinobu Koguchi

David Philip Cook

John E Hearst

David N Cook

Akbar Nayeem

Michael Quigley

Hadia Lemar

William S Luckett, Jr

Kenneth M Stedman

James R Laidler

Helena Maria Hoen

Alejandro F Alice

Thomas W Dubensky

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

The present invention relates to the preparation and use in primates of whole organismvaccines in which the MEP pathway is disrupted such that synthesis of HMBPP by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active MEP pathway are used in vaccine methods, the &#x3b3;&#x3b4; T cell response dominates, potentially clearing the vaccine strain via &#x3b3;&#x3b4; T cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of CD4and CD8&#x3b1;&#x3b2; T cell responses, specific for listerial-encoded antigens. By disrupting the MEP pathway, activation and expansion of &#x3b3;&#x3b4; T cells is limited in the recipient primate, resulting in resulting in an increase in the magnitude and duration of inflammation and in the magnitude and duration of antigen presentation by the cellular vaccine.

Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof

It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as a T cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.

Immunogenic compositions comprising silicified virus and methods of use

Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically activethat encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.

[object Object]

The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.

Methods and compositions for inducing an immune response to EGFRvIII

Methods and compositions using listeria for enhancing immunogenicity by prime boost

Methods and compositions using listeria for adjuvant treatment of cancer

Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

Modified free-living microbes, vaccine compositions and methods of use thereof

Growing community of inventors

Portland, OR, United States of America

Keith Sadoon Bahjat